Impact of Hospital Practice Factors on Mortality in Patients Hospitalized for Heart Failure in Japan
— An Analysis of a Large Number of Health Records From a Nationwide Claims-Based Database, the JROAD-DPC —

Hidetaka Kaku, MD; Kouta Funakoshi, MD; Tomomi Ide, MD, PhD; Takeo Fujino, MD, PhD; Shouji Matsushima, MD, PhD; Kisho Ohtani, MD, PhD; Taiki Higo, MD; Michikazu Nakai, PhD; Yoko Sumita; Kunihiro Nishimura, MD, PhD; Yoshihiro Miyamoto, MD, PhD; Toshihisa Anzai, MD, PhD; Hiroyuki Tsutsui, MD, PhD

Background: An inverse relationship exists between hospital case volume and mortality in patients with heart failure (HF). However, hospital performance factors associated with mortality in HF patients have not been examined. We aimed to identify these using exploratory factor analysis and assess the relationship between these factors and 7-day, 30-day, and in-hospital mortality among HF patients in Japan.

Methods and Results: We analyzed the records of 198,861 patients admitted to 683 certified hospitals of the Japanese Circulation Society between 2012 and 2014. Records were obtained from the nationwide database of the Japanese Registry Of All cardiac and vascular Diseases-Diagnostic Procedure Combination (JROAD-DPC). Using exploratory factor analysis, 90 hospital survey items were grouped into 5 factors, according to their collinearity: “Interventional cardiology”, “Cardiovascular surgery”, “Pediatric cardiology”, “Electrophysiology” and “Cardiac rehabilitation”. Multivariable logistic regression analysis was performed to determine the association between these factors and mortality. The 30-day mortality was 8.0%. Multivariable logistic regression analysis showed the “Pediatric cardiology” (odds ratio (OR) 0.677, 95% confidence interval [CI]: 0.628–0.729, P<0.0001), “Electrophysiology” (OR 0.876, 95% CI: 0.832–0.923, P<0.0001), and “Cardiac rehabilitation” (OR 0.832, 95% CI: 0.792–0.873, P<0.0001) factors were associated with lower mortality. In contrast, “Interventional cardiology” (OR 1.167, 95% CI: 1.070–1.272, P<0.0001) was associated with higher mortality.

Conclusions: Hospital factors, including various cardiovascular therapeutic practices, may be associated with the early death of HF patients.

Key Words: Cardiac rehabilitation; Electrophysiology; Exploratory factor analysis; Heart failure

Heart failure (HF) is one of the most common causes of hospitalization, with high in-hospital mortality and rehospitalization rates.1 Numerous studies from clinical trials and registries have identified a number of clinical and biochemical factors as potential prognostic factors for poor outcomes among HF patients.2–6 These factors include demographics, medical history, symptoms and signs, and laboratory biomarkers. However, the outcomes of HF patients may be influenced not only by individual characteristics, but also by hospital practices. Admission to higher-volume hospitals is associated with lower mortality of HF patients, as well as acute myocardial infarction, which means hospital case volume is an indicator of the quality of hospital practice.7 In Japan, the case volume-outcome relationship has been confirmed in HF using a nationwide administrative database of patients with cardiovascular diseases (Japanese Registry Of All cardiac and vascular Diseases: JROAD).8 Multivariable regression analysis has also shown that a higher hospital volume is independently associated with lower rates of 7-day, 30-day, and in-hospital mortality.8

Hospital case volume is a representative clinical indicator, but may not be an appropriate factor for assessing optimal medical care for HF, because HF care involves various...
Hospital practices, including interventional or non-interventional treatment of coronary artery disease (CAD), arrhythmia, and congenital heart disease; for example, the evidence-based HF therapies for left ventricular dysfunction. However, there are no studies demonstrating the relationship between hospital practice factors and outcomes in HF, partly because hospital therapeutic practices around HF are considered to be numerous and varied, as with other cardiovascular diseases. Moreover, analyses of the interrelationship between these factors are very complicated. For example, the number of coronary artery bypass grafting (CABG) cases will be associated with the number of cardiovascular surgeons and other arterial surgeries.

Exploratory factor analysis is a statistical grouping technique that simplifies multivariate data when there is a large number of intercorrelated variables. It is used to eliminate multicollinearity and identify the “factors” of independent prognostic markers. Exploratory factor analysis groups many variables into a smaller set of independent “factors” according to basic underlying relationships among variables.
“Factors” are fewer in number than the original variables and useful in subsequent statistical analysis (i.e., predictive regression models). This analytical method has been widely used in the social sciences and also used an approach to analyzing multiple biomarkers in cardiovascular research.  

Methods

Study Design and Hospital and Patient Database

This research was a retrospective, nationwide, observational cohort study. The detailed methods of JROAD and JROAD-DPC were published in our previous study. The JROAD study was launched in 2004 to assess the clinical activity of each Japanese institution’s cardiovascular beds. DPC used data from the Japanese Diagnosis Procedure Combination/Per Diem Payment System (DPC/PDPS), which includes the following individual data: patient age and sex, main diagnosis and comorbidities, drugs and devices, diagnostic and therapeutic procedures, length of stay, and discharge status. The JROAD-DPC database is the combination of JROAD and DPC-based claim data. In brief, all Japanese Circulation Society (JCS)-certified teaching hospitals with cardiovascular beds, except for those with stroke beds, participated in the JROAD. A JCS-certified teaching hospital is a facility of a standard that can provide the curriculum necessary for a JCS board-certified cardiologist, and with sufficient numbers of cases and a medical education environment. A total of 1,612 hospitals agreed to participate in the JROAD-DPC database study. Hospitals with ≤10 patients hospitalized with HF per year were excluded. Thus 1,160 hospitals with 224,594 patient records were used to determine the clustering of hospital survey items (Figure A). The records of patients admitted to hospital with acute HF based on the International Classification of Diseases-10 diagnosis codes related to HF (HF: I50.0; congestive HF, I50.1; left ventricular failure; I50.9; HF, unspecified) were identified and extracted. This method of extracting the coding was the same as used in our previous JROAD-DPC study.  

Patients

The following data were extracted from the database: unique hospital identifier, patient’s age and sex, diagnoses, comorbidities at admission, in-hospital use of medications, New York Heart Association (NYHA) classification on admission, and discharge status. NYHA classification on admission, collected from the DPC, was determined by the attending physician in each case. Comorbidities were determined primarily from the International Classification of Diseases-10 codes, but they were also checked against the medications and procedures each patient received/underwent to determine if these were consistent with the code data. A total of 224,594 hospitalization records were collected between April 1, 2012, and March 31, 2014, from 1,160 hospitals. After exclusion of 477 hospitals that did not agree to provide DPC data, 683 hospitals with 198,861 DPC data records were used for exploratory factor analysis to identify clusters associated with the prognosis of HF (Figure B).

Hospital Practice Factors Identified by Exploratory Factor Analysis

The hospital survey items related to practice volume and structural indicators used for exploratory factor analysis are listed in Supplementary Table 1. First, we collected “hospital survey items” from the JROAD survey. We utilized the term “items”, or “hospital survey items” such as the numbers of elective percutaneous coronary intervention (PCI), listed in Supplementary Table 1. We performed exploratory factor analysis using these items, and the new groups, which we defined as “factors” or “hospital practice factors”, emerged. We interpreted each “factor” and named it based on the results of items with larger factor loading scores, because the magnitude of factor loading represents the contribution to the factor. We chose the maximum number of factors by gradually increasing the number of factors that could be interpreted, and we named the factors representative items with stronger factor loading in each

| Table 1. Baseline Characteristics of Study Patients |
|----------------------|----------------------|
| n | 198,861 |
| Male, n (%) | 104,893 (52.7%) |
| Age, years (mean±SD) | 77.8±12.9 |
| Length of hospitalization, days (mean±SD) | 22.8±20.9 |
| NYHA class, n (%) (n=178,268) | |
| I | 14,132 (7.9%) |
| II | 49,854 (28.0%) |
| III | 59,577 (33.4%) |
| IV | 54,705 (30.7%) |
| Comorbidity, n (%) | |
| Hypertension | 100,927 (50.8%) |
| Diabetes mellitus | 52,156 (26.2%) |
| Hyperlipidemia | 33,938 (17.1%) |
| COPD | 13,935 (7.0%) |
| Ischemic heart disease | 61,332 (30.8%) |
| Cardiomyopathy | 10,641 (5.7%) |
| Charlon comorbidity index, (median, [IQR]) | 2 [1, 3] |
| Discharge medication, n (%) (n=177,229) | |
| ACEI | 33,388 (18.8%) |
| ARB | 52,560 (29.7%) |
| Calcium-channel blocker | 44,307 (25.0%) |
| β-blocker | 82,590 (46.6%) |
| Loop diuretic | 85,664 (48.3%) |
| Spironolactone | 61,370 (34.6%) |
| Oral antidiabetic drugs | 26,664 (15.0%) |
| Insulin | 3,496 (2.0%) |
| Statin | 42,150 (23.8%) |
| Warfarin | 50,775 (28.6%) |
| DOAC | 11,004 (6.2%) |
| Aspirin | 53,228 (30.0%) |

ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; DOAC, direct oral anticoagulant; NYHA, New York Heart Association.
factor. Factor loading is a value indicating the influence of factors on variables, “items” in this case, which means factors or items are correlated according to the magnitude of the value of factor loading. In other words, if the factor loading score is larger, the correlation between factors and items is stronger. The conventional exploratory factor analysis approach is based on changing strong factor loadings, for example, those in excess of 0.40.

We performed exploratory factor analysis using oblique rotation with the quartimin method after replacement with logarithmic normal distribution and then grouped 90 hospital survey items of practice volume and structural indicators into several factors. We performed exploratory factor analysis and grouped 90 items from the JROAD survey after excluding 8 items that had a strong confounding relationship with endpoint and adjusted variables in this study, 3 items related to hospital case volume of HF, 3 items related to the endpoint of this study, and 2 items related to DPC cording number.

| Table 2. Baseline Characteristics of Hospitals (n=683) Participating in JROAD-DPC | Overall | Median, [IQR] |
|---|---|---|
| No. of beds | 400, [300, 558] |
| No. of admissions for HF | 158, [101, 234] |
| Acute decompensated HF | 44, [10, 117] |
| No. of patients with chronic HF | 42, [10, 98] |
| In-hospital deaths of HF patients | 12, [6, 19] |
| Cardiology department |  |
| No. of beds | 35, [30, 45] |
| No. of cardiologists | 6, [4, 9] |
| No. of board-certified cardiologists | 4, [3, 6] |
| No. of hospitalized patients in cardiology department | 809, [518, 1,203] |
| CCU, n (%) | 574 (84.0%) |
| Cardiac catheterization laboratory, n (%) | 668 (97.8%) |
| PCI procedures | 655 (95.9%) |
| Cardiovascular surgery department | 406 (59.4%) |
| No. of beds | 5, [0, 15] |
| No. of cardiovascular surgeons | 2, [0, 4] |
| No. of hospitalized patients | 74, [0, 217] |
| Pediatric cardiology department | 151 (22.1%) |
| No. of beds | 0, [0, 0] |
| No. of pediatric cardiologists | 0, [0, 0] |
| No. of hospitalized patients | 0, [0, 0] |
| Cardiac rehabilitation | 334 (48.9%) |
| Cardiac rehabilitation (new enrollment cases) | 0, [0, 195] |
| Total no. of cardiac rehabilitation patients | 0, [0, 2,503] |

**CCU,** coronary care unit; **HF,** heart failure; **PCI,** percutaneous coronary intervention.

**Table 3. Annual Volumes of Hospitals Participating in JROAD-DPC**

| Procedure | Median, [IQR] |
|---|---|
| Transthoracic echocardiography | 3,103, [2,001, 4,965] |
| Transesophageal echocardiography | 21, [5, 70] |
| Coronary angiography | 333, [181, 594] |
| Ventriculography | 60, [10, 205] |
| Intravascular ultrasound | 132, [52, 252] |
| Myocardial biopsy | 1, [0, 6] |
| Electrophysiologic study | 5, [0, 19] |
| Catheterization for CHD (diagnosis) | 0, [0, 3] |
| Emergency PCI | 50, [23, 88] |
| Elective PCI | 125, [60, 212] |
| Plain old balloon angioplasty (per lesion) | 14, [3, 37] |
| Plain old balloon angioplasty (per patient) | 15, [5, 31] |
| Bare metal stents (per lesion) | 25, [6, 56] |
| Bare metal stents (per patient) | 25, [9, 54] |
| Drug-eluting stents (per lesion) | 124, [39, 240] |
| Drug-eluting stents (per patients) | 108, [47, 201] |
| Rotablation atherectomy (per lesion) | 0, [0, 6] |
| Rotablation atherectomy (per patient) | 0, [0, 6] |
| Emergency PCI for AMI | 38, [18, 66] |
| Percutaneous transluminal angiography (per patient) | 21, [7, 57] |
| Catheterization for CHD (intervention) | 0, [0, 0] |
| Intra-aortic balloon pumping | 11, [4, 28] |
| Percutaneous cardiopulmonary support | 2, [0, 7] |
| Left ventricular assist device | 0, [0, 0] |
| Pacemaker implantation | 26, [14, 41] |
| Pacemaker implantation (exchange) | 11, [6, 20] |
| ICD implantation | 0, [0, 5] |
| ICD implantation (exchange) | 0, [0, 1] |
| Catheter ablation | 3, [0, 42] |
| CRT | 0, [0, 0] |
| CRT defibrillator implantation | 0, [0, 4] |
| Cardiac surgery | 8, [0, 83] |
| CABG (on-pump) | 0, [0, 12] |
| CABG (off-pump) | 0, [0, 11] |
| Surgery (valvuloplasty) | 0, [0, 9] |
| Surgery (valve replacement) | 1, [0, 23] |
| Surgery of thoracic aortic dissection | 0, [0, 8] |
| Surgery of thoracic aortic aneurysm | 0, [0, 8] |
| Surgery (abdominal aorta+peripheral artery) | 7, [0, 54] |
| Thoracic endovascular aortic repair | 0, [0, 2] |
| Abdominal aortic stent-grafting | 0, [0, 10] |
| Surgery of CHD | 0, [0, 1] |

**AMI,** acute myocardial infarction; **CABG,** coronary artery bypass grafting; **CHD,** congenital heart disease; **CRT,** cardiac resynchronization therapy; **ICD,** implantable cardioverter defibrillator; **PCI,** percutaneous coronary intervention.

**Ethics Statement**

This study was conducted according to the principles of the Declaration of Helsinki. JROAD and JROAD-DPC are secondary analyses of a nationwide survey conducted by the JCS. The research plan was designed by the authors and approved by the institutional review boards of the National Cerebral and Cardiovascular Center (NCVC) and Kyushu University, which waived the requirement for individual informed consent based on the “opt-out” principle applied. Each hospital anonymized patients’ ID using code-change equations applied to the original DPC data, which was sent to the Ministry of Health, Labour and Welfare, and NCVC managed the database. NCVC notified patients that their information was being collected by this study through homepages or posters in each hospital.
Patients could choose to have their information excluded (opt-out).

**Statistical Analysis**
All normally distributed continuous variables are presented as mean ± SD and the unpaired t-test was used to compare groups. All non-normal distributed continuous variables are presented as median and quartiles (median, [interquartile range: IQR]) and the Wilcoxon signed-rank test was used to compare groups. Non-continuous and categorical variables are presented as percentages and compared using the chi-square test or Fisher’s exact test. A P-value <0.05 was considered statistically significant. The analyses were performed using SAS® 9.4 (SAS Institute Inc., Cary, NC, USA) and JMP® 13 (SAS Institute Inc.).

We categorized hospitals into quartiles based on the factor score: quartile 1 (very low), quartile 2 (low), quartile 3 (high), and quartile 4 (very high). Each factor level was modelled in quartiles with odds ratios (ORs) referring to the relative risk between Q1 and Q4. To determine the

| Table 4. Factor Loading of Items of Practice Volume and Structural Indicators After Exploratory Factor Analysis Using Oblique Rotation and Quartimin Method |
|---|
| **Factor** | 1 | 2 | 3 | 4 | 5 |
| **1. Interventionsal cardiology** | | | | | |
| Elective PCI | 0.928 | 0.059 | -0.035 | -0.056 | 0.026 |
| Emergency PCI | 0.916 | 0.102 | -0.014 | -0.029 | -0.008 |
| Emergency PCI for AMI | 0.906 | 0.084 | -0.004 | -0.038 | -0.018 |
| Drug-eluting stents (per patient) | 0.884 | 0.033 | 0.020 | -0.139 | 0.026 |
| Coronary angiography | 0.880 | 0.042 | -0.005 | -0.004 | 0.023 |
| Intravascular ultrasound | 0.850 | 0.047 | 0.014 | -0.018 | -0.036 |
| Drug-eluting stents (per lesion) | 0.796 | -0.054 | 0.009 | -0.082 | -0.040 |
| Bare metal stents (per patient) | 0.775 | 0.048 | 0.070 | -0.094 | 0.059 |
| No. of AMI | 0.771 | 0.150 | -0.040 | 0.021 | 0.022 |
| Plain old balloon angioplasty (per patient) | 0.741 | 0.074 | 0.016 | -0.098 | 0.047 |
| Bare metal stents (per lesion) | 0.735 | -0.021 | 0.067 | -0.075 | 0.070 |
| Pacemaker implantation | 0.695 | 0.165 | -0.022 | 0.124 | 0.013 |
| Plain old balloon angioplasty (per lesion) | 0.682 | 0.013 | 0.015 | -0.085 | 0.002 |
| Intra-aortic balloon pumping | 0.639 | 0.321 | -0.024 | 0.053 | 0.030 |
| Ventrilography | 0.601 | -0.019 | 0.095 | 0.001 | -0.051 |
| No. of hospitalized patients in cardiology department | 0.557 | 0.063 | -0.087 | 0.166 | 0.103 |
| Percutaneous transluminal angiography (per patient) | 0.537 | 0.238 | -0.056 | -0.049 | 0.079 |
| Coronary computed tomography angiography | 0.507 | 0.146 | -0.016 | -0.011 | 0.133 |
| Aortography | 0.487 | 0.015 | 0.084 | 0.023 | 0.024 |
| Inferior vena cava filter placement | 0.468 | 0.106 | 0.066 | 0.110 | 0.007 |
| Thoracoscopic echocardiography | 0.449 | 0.167 | 0.057 | 0.190 | 0.122 |
| No. of admissions to CCU | 0.448 | 0.231 | 0.053 | 0.023 | 0.025 |
| Pacemaker implantation (exchange) | 0.419 | 0.229 | 0.017 | 0.203 | 0.005 |

| **2. Cardiovascular surgery** | | | | | |
| No. of hospitalized patients (cardiovascular surgery) | 0.112 | 0.902 | 0.042 | -0.139 | 0.023 |
| Surgery (valve replacement) | 0.059 | 0.894 | 0.004 | 0.057 | 0.052 |
| Cardiac surgery | 0.064 | 0.882 | 0.006 | 0.002 | 0.054 |
| No. of beds in cardiovascular surgery department | 0.097 | 0.873 | 0.054 | -0.116 | 0.035 |
| Surgery (abdominal aorta+peripheral artery) | 0.098 | 0.854 | 0.021 | -0.088 | 0.034 |
| Average length of hospital stay (cardiovascular surgery), days | 0.145 | 0.835 | 0.006 | -0.208 | 0.017 |
| CABG (on-pump) | 0.068 | 0.834 | -0.011 | -0.018 | 0.075 |
| CABG (off-pump) | 0.031 | 0.794 | -0.012 | 0.094 | 0.049 |
| No. of cardiovascular surgeons | 0.048 | 0.791 | 0.154 | 0.050 | 0.055 |
| Surgery (valvuloplasty) | 0.009 | 0.783 | 0.057 | 0.120 | 0.085 |
| Surgery of thoracic aortic dissection | 0.010 | 0.771 | 0.052 | 0.114 | 0.092 |
| Surgery of thoracic aortic aneurysm | -0.003 | 0.755 | 0.071 | 0.155 | 0.109 |
| Abdominal aortic stent-grafting | -0.005 | 0.650 | 0.108 | 0.126 | 0.088 |
| Rotablation atherectomy (per patient) | 0.112 | 0.585 | -0.063 | 0.166 | 0.105 |
| Rotablation atherectomy (per lesion) | 0.149 | 0.555 | -0.051 | 0.160 | 0.052 |
| Thoracic endovascular aortic repair | -0.071 | 0.538 | 0.115 | 0.253 | 0.106 |
| Percutaneous cardiopulmonary support | 0.281 | 0.460 | 0.039 | 0.122 | 0.049 |

(Table 4 continued the next page.)
Hospital Practice Factors and Mortality in HF

3. Pediatric cardiology

| Factor | 1  | 2   | 3     | 4     | 5     |
|--------|----|-----|-------|-------|-------|
| No. of hospitalized patients (pediatric cardiology) | 0.022 | -0.026 | 0.998 | -0.051 | -0.012 |
| No. of pediatric cardiologists | -0.001 | -0.030 | 0.973 | -0.019 | -0.005 |
| No. of beds in pediatric cardiology department | 0.015 | -0.035 | 0.939 | -0.056 | -0.001 |
| Average length of hospital stay (pediatric cardiology), days | 0.049 | -0.024 | 0.864 | -0.127 | -0.009 |
| Catheterization for CHD (intervention) | -0.013 | -0.006 | 0.657 | 0.092 | 0.063 |
| Catheterization for CHD (diagnosis) | 0.090 | 0.097 | 0.618 | 0.167 | 0.044 |
| Surgery of CHD | -0.048 | 0.326 | 0.592 | 0.093 | 0.052 |

4. Electrophysiology

| Factor | 1  | 2   | 3     | 4     | 5     |
|--------|----|-----|-------|-------|-------|
| ICD implantation (exchange) | -0.064 | 0.312 | 0.137 | 0.574 | 0.060 |
| ICD implantation | -0.036 | 0.484 | 0.039 | 0.558 | 0.051 |
| CRT defibrillator implantation | -0.050 | 0.479 | 0.027 | 0.524 | 0.087 |
| Signal-averaged ECG | 0.022 | 0.166 | 0.109 | 0.500 | 0.000 |
| Catheter ablation | 0.122 | 0.350 | 0.004 | 0.492 | 0.052 |
| No. of cardiologists | 0.293 | 0.154 | 0.139 | 0.453 | 0.107 |
| CRT | -0.049 | 0.336 | 0.088 | 0.436 | 0.065 |

5. Cardiac rehabilitation

| Factor | 1  | 2   | 3     | 4     | 5     |
|--------|----|-----|-------|-------|-------|
| Total no. of cardiac rehabilitation patients | -0.063 | 0.091 | -0.036 | -0.125 | 1.008 |
| Cardiac rehabilitation (new enrollment cases) | -0.051 | 0.107 | -0.044 | -0.104 | 1.004 |
| Dispersibility | 23.68 | 25.42 | 12.94 | 16.64 | 11.42 |
| Contribution ratio | 26.31 | 28.24 | 14.38 | 18.49 | 12.69 |
| Cumulative contribution ratio | 26.31 | 54.55 | 68.93 | 87.42 | 100.12 |

ECG, electrocardiography. Other abbreviations as in Tables 1,2.

association between the factors and 7-day, 30-day, and in-hospital mortality rates in patients hospitalized for HF, we used a univariate analysis and multivariable logistic regression model. We chose hospital HF case volume, including acute decompensated HF (ADHF) and chronic HF (CHF), as fixed effects, and age, sex, Charlson comorbidity index, NYHA class for HF as patient effects and factors chosen by exploratory factor analysis. To confirm the results, we performed 2 sensitivity analyses using a representative example from each factor with a large factor loading and using another group that excluded the patients without oral medications for HF.

Results

Baseline Characteristics of the Study Patients (Table 1)
We studied 198,861 HF patients (53% male) with an age of 77.8 ± 12.9 (mean ± SD) years. The NYHA functional class was I in 7.9%, II in 28.0%, III in 33.4%, and IV in 30.7% of patients. Among them, 51% of HF patients had hypertension, 26% had diabetes mellitus, 31% had CAD, and 5.7% had cardiomyopathy (Table 1). In terms of medications at discharge, 48% of the patients took renin-angiotensin system (RAS) inhibitors, 47% took β-blockers, 48% took loop diuretics, and 35% took spironolactone.

Baseline Characteristics of the Study Hospitals (Tables 2,3)
Patients were hospitalized in 683 JROAD-DPC-participating hospitals, in which a median of 158 [101, 234] patients are admitted annually for HF. A coronary care unit (CCU) was equipped in 84% of the hospitals; 59% of the hospitals had a cardiovascular surgery department, 22% had a pediatric cardiology department, 98% had a cardiac catheterization laboratory, and 49% had a cardiac rehabilitation program (Table 2).

The annual volume of the therapeutic practices is shown in Table 3. The numbers of patients who underwent emergency and elective PCI were 50 [23, 88] and 125 [60, 212] (median [IQR]), respectively. Implantation of a cardioverter defibrillator was performed in 0 [0, 5] cases. The number of new enrollments in the cardiac rehabilitation program was 0 [0, 195].

Hospital Practice Factors Determined by Exploratory Factor Analysis
Table 4 shows the exploratory factor analysis results for hospitals with the highest contribution to the factors by factor loading. There was a reduction in variable numbers from the original 90 variables to 5 composite factors: (1) “Interventional cardiology” factor with strong loadings of items such as coronary intervention and angiography, (2) “Cardiovascular surgery” factor with positive loadings of items such as number of patients hospitalized for cardiovascular surgery, (3) “Pediatric cardiology” factor comprising items such as number of hospitalized pediatric patients, (4) “Electrophysiology” factor comprising items such as implantation of defibrillator and catheter ablation, and (5) “Cardiac rehabilitation” factor comprising the volume of cardiac rehabilitation patients. The combination of these 5 factors explained approximately 100% of the variance in the original data: factor 1, 26.3%; factor 2, 28.2%; factor 3, 14.4%; factor 4, 18.5%; and factor 5, 16.7%. There were only modest correlations between each factor (Supplementary Table 2), because we interpreted the correlation to be strong if the values were ≥ 0.7.
Sensitivity Analysis
In order to confirm these results, we performed a sensitivity analysis using representative examples with large factor loadings for each factor (Table 6). “Elective PCI” was selected as a representative example from the “Interventional cardiology” factor and “ICD [implantable cardioverter defibrillator] implantation” was selected from the “Electrophysiology” factor. The presence or absence of a department of cardiovascular surgery, a department of pediatric cardiology, and cardiac rehabilitation program were used for the analysis, because 41%, 78% and 51% of hospitals did not have a department of cardiovascular surgery, department of pediatric cardiology and cardiac rehabilitation programs, respectively. Therefore, the ORs

Association Between Hospital Practice Factors and Mortality
The 7-day, 30-day, and in-hospital mortality were 4.0%, 8.0%, and 10.8%, respectively (Table 2). The association among the 5 hospital practice factors clustered using the exploratory factor analysis was assessed by logistic regression analysis (Table 5).

The “Pediatric cardiology”, “Electrophysiology”, and “Cardiac rehabilitation” factors were associated with lower 7-day, 30-day, and in-hospital mortality in HF patients. In contrast, the “Interventional cardiology” factor was associated with higher 7-day and 30-day mortality. The “Cardiovascular surgery” factor did not show any significant association with mortality.

### Table 5. OR and 95% CI of Mortality Rates in Patients With HF According to Hospital Practice Factors

| Table 5. OR and 95% CI of Mortality Rates in Patients With HF According to Hospital Practice Factors |
|---------------------------------------------------------------------------------------------------|
| **Quartile** | **Hospitals (n)** | **Patients (n)** | **7-day mortality** | **30-day mortality** | **In-hospital mortality** |
|-------------|-----------------|-----------------|---------------------|---------------------|------------------------|
| **Factor 1: Interventional cardiology** | | | | | |
| Q1 | 170 | 27,449 | Ref. | <0.0001 | Ref. | <0.0001 | Ref. | 0.0158 |
| Q2 | 171 | 41,614 | 0.988 (0.901–1.082) | 1.020 (0.954–1.091) | 0.979 (0.923–1.038) |
| Q3 | 171 | 54,719 | 1.192 (1.072–1.326) | 1.105 (1.022–1.195) | 0.988 (0.932–1.069) |
| Q4 | 171 | 75,079 | 1.322 (1.174–1.488) | 1.167 (1.070–1.272) | 1.037 (0.962–1.118) |
| **Factor 2: Cardiovascular surgery** | | | | | |
| Q1 | 170 | 36,094 | Ref. | 0.4016 | Ref. | 0.4071 | Ref. | 0.2506 |
| Q2 | 171 | 37,484 | 0.988 (0.802–0.939) | 0.917 (0.866–0.972) | 0.916 (0.871–0.964) |
| Q3 | 171 | 55,178 | 0.947 (0.869–1.031) | 1.008 (0.947–1.074) | 1.041 (0.985–1.100) |
| Q4 | 171 | 70,105 | 0.907 (0.815–1.009) | 0.986 (0.912–1.065) | 0.989 (0.924–1.059) |
| **Factor 3: Pediatric cardiology** | | | | | |
| Q1 | 170 | 34,042 | Ref. | <0.0001 | Ref. | <0.0001 | Ref. | <0.0001 |
| Q2 | 171 | 38,881 | 0.982 (0.817–0.952) | 0.900 (0.851–0.953) | 0.879 (0.836–0.924) |
| Q3 | 171 | 54,357 | 0.660 (0.609–0.715) | 0.732 (0.690–0.777) | 0.757 (0.718–0.798) |
| Q4 | 171 | 71,581 | 0.586 (0.529–0.648) | 0.677 (0.628–0.729) | 0.684 (0.641–0.731) |
| **Factor 4: Electrophysiology** | | | | | |
| Q1 | 170 | 60,005 | Ref. | <0.0001 | Ref. | <0.0001 | Ref. | <0.0001 |
| Q2 | 171 | 47,375 | 0.953 (0.888–1.022) | 1.004 (0.954–1.057) | 0.998 (0.954–1.044) |
| Q3 | 171 | 40,486 | 0.829 (0.769–0.894) | 0.878 (0.831–0.928) | 0.914 (0.871–0.960) |
| Q4 | 171 | 50,995 | 0.844 (0.786–0.906) | 0.876 (0.832–0.923) | 0.895 (0.855–0.937) |
| **Factor 5: Cardiac rehabilitation** | | | | | |
| Q1 | 170 | 52,569 | Ref. | <0.0001 | Ref. | <0.0001 | Ref. | <0.0001 |
| Q2 | 171 | 30,485 | 0.798 (0.728–0.874) | 0.862 (0.805–0.923) | 0.898 (0.846–0.953) |
| Q3 | 171 | 50,825 | 0.813 (0.759–0.871) | 0.879 (0.835–0.924) | 0.927 (0.887–0.970) |
| Q4 | 171 | 64,982 | 0.707 (0.661–0.756) | 0.832 (0.792–0.873) | 0.872 (0.835–0.910) |

ORs and 95% CIs of mortality rates in patients with heart failure (HF) among 4 groups defined by factor analysis. The 5 factor clusters: “Interventional cardiology”, “Cardiovascular surgery”, “Pediatric cardiology”, “Electrophysiology” and “Cardiac rehabilitation”. Quartiles, based on the factor score: quartile 1 (Q1: very low), quartile 2 (Q2: low), quartile 3 (Q3: high), quartile 4 (Q4: very high). Multivariate, adjusted for age, sex, Charlson comorbidity index, NYHA class for HF, hospital case volume of HF and 5 factor clusters. CI, confidence intervals; NYHA, New York Heart Association; OR, odds ratios.
were estimated according to the presence of these items, instead of each factor. The presence of a department of pediatric cardiology, performing ICD implantation and the presence of a program of cardiac rehabilitation were associated with lower mortality. In contrast, “Performing cardiac surgery” was associated with higher mortality. “Elective PCI” was associated with lower in-hospital mortality; however, the reason why the number of elective PCIs was a hospital factor affecting the short-term mortality of HF could not be explained. These sensitivity analyses demonstrated a similar tendency to the results of the factor analysis, so we confirmed this model. Finally, we performed another sensitivity analysis using patient subgroups that were prescribed ≥1 medications among RAS inhibitors, β-blockers, mineralocorticoid receptor antagonists and loop diuretics during hospitalization or at discharge (Table 7). The baseline characteristics of this subgroup were shown in Supplementary Table 3, and the results of multivariate logistic regression analyses revealed factors 2, 3, 4 and 5 showed the same tendency, and factor 1 did not show any significant difference, which was consistent with our main analysis.

**Discussion**

In the present study, we demonstrated that the clustering of 90 survey items of hospital performance sampled using the JROAD database was feasible using exploratory factor analysis. This approach could be useful to explore the interaction between different hospital practice factors and the mortality of HF patients. The present analysis found that hospital practice factors such as “Pediatric cardiology”, “Electrophysiology”, and “Cardiac rehabilitation” were associated with lower mortality in hospitalized HF patients, whereas “Interventional cardiology” factor was associated with higher mortality.

Numerous previous studies have demonstrated the prognostic impact of various demographic, clinical, and biochemical markers in patients with HF. In terms of hospital features, the relationship between hospital case volume and outcomes in patients with HF has been shown. However, it is unlikely that a single marker of hospital performance could completely reflect the characteristics of hospital care systems. Thus, our statistical analysis approach could increase our understanding of real hospital practice factors and predict outcomes of patients with HF.

**Assessment of Hospital Practice by Exploratory Factor Analysis**

Hospital practice factors involved in HF management are complicated, and statistical assessment of hospital factors is problematic because it involves multiple practices. Exploratory factor analysis may be useful to assess the...
750 KAKU H et al.

Egnot et al. demonstrated that high inflammatory and coagulation markers were better associated with femoral atherosclerosis using exploratory factor analysis. The present study is the first to identify the factors of multiple hospital survey items in the management of HF, and their prognostic ability. Importantly, we have shown that this approach can also be applied to structural indicators.

**Composition of Factor Clusters**

The purpose of our study was to determine the institutional characteristics that define the short-term prognosis of HF. We categorized 90 survey items of hospital performance contributory role of the various factors involved in the management of HF patients. This multivariable statistical technique is a standard approach for investigations when multiple, highly correlated variables are involved. Exploratory factor analyses are widely used in the social sciences, and has been applied to the analysis of multiple biomarkers in studies of cardiovascular medicine. Tziakas et al. used an exploratory factor analysis approach and reported that markers reflecting anti-inflammatory mechanisms were better prognostic markers in patients with an acute coronary syndrome. Manhenke et al. demonstrated that the clustering of 37 circulation biomarkers using exploratory factor analysis was useful to explore the biological interactions between different biomarkers in cardiovascular disease. Egnot et al. demonstrated that high inflammatory and coagulation markers were better associated with femoral atherosclerosis using exploratory factor analysis.

The study identified the following five factor clusters: "Interventional cardiology", "Cardiovascular surgery", "Pediatric cardiology", "Electrophysiology" and "Cardiac rehabilitation". Quartiles, based on the factor score: quartile 1 (Q1: very low), quartile 2 (Q2: low), quartile 3 (Q3: high), quartile 4 (Q4: very high). Multivariate, adjusted for age, sex, Charlson comorbidity index, NYHA class for HF, hospital case volume of HF and 5 factor clusters. Abbreviations as in Tables 2 and 9.

| Factor 1: Interventional cardiology | 7-day mortality | 30-day mortality | In-Hospital mortality |
|-----------------------------------|----------------|-----------------|---------------------|
| **Quartile** | **Hospitals (n)** | **Patients (n)** | **OR (95% CI)** | **P for trend** | **OR (95% CI)** | **P for trend** | **OR (95% CI)** | **P for trend** |
| Q1 | 170 | 24,783 | Ref. | 0.1447 | Ref. | 0.1603 | Ref. | 0.2756 |
| Q2 | 171 | 38,155 | 1.014 | (0.900–1.142) | 1.036 | (0.960–1.119) | 0.980 | (0.919–1.045) |
| Q3 | 171 | 50,265 | 1.041 | (0.904–1.200) | 1.041 | (0.952–1.138) | 0.934 | (0.866–1.006) |
| Q4 | 171 | 70,001 | 1.139 | (0.975–1.331) | 1.072 | (0.972–1.183) | 0.949 | (0.873–1.030) |

**Factor 2: Cardiovascular surgery**

| **Quartile** | **Hospitals (n)** | **Patients (n)** | **OR (95% CI)** | **P for trend** | **OR (95% CI)** | **P for trend** | **OR (95% CI)** | **P for trend** |
|-------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Q1 | 170 | 32,862 | Ref. | 0.7047 | Ref. | 0.0944 | Ref. | 0.0658 |
| Q2 | 171 | 34,229 | 0.885 | (0.798–0.981) | 0.933 | (0.873–0.997) | 0.927 | (0.877–0.981) |
| Q3 | 171 | 50,522 | 0.944 | (0.843–1.057) | 1.012 | (0.941–1.087) | 1.051 | (0.989–1.117) |
| Q4 | 171 | 65,591 | 1.057 | (0.920–1.215) | 1.061 | (0.971–1.158) | 1.039 | (0.965–1.119) |

**Factor 3: Pediatric cardiology**

| **Quartile** | **Hospitals (n)** | **Patients (n)** | **OR (95% CI)** | **P for trend** | **OR (95% CI)** | **P for trend** | **OR (95% CI)** | **P for trend** |
|-------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Q1 | 170 | 30,623 | Ref. | <0.0001 | Ref. | <0.0001 | Ref. | <0.0001 |
| Q2 | 171 | 35,466 | 0.901 | (0.813–0.997) | 0.911 | (0.853–0.973) | 0.886 | (0.838–0.936) |
| Q3 | 171 | 50,221 | 0.761 | (0.683–0.849) | 0.788 | (0.736–0.845) | 0.860 | (0.760–0.854) |
| Q4 | 171 | 66,894 | 0.676 | (0.589–0.776) | 0.737 | (0.676–0.803) | 0.733 | (0.682–0.788) |

**Factor 4: Electrophysiology**

| **Quartile** | **Hospitals (n)** | **Patients (n)** | **OR (95% CI)** | **P for trend** | **OR (95% CI)** | **P for trend** | **OR (95% CI)** | **P for trend** |
|-------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Q1 | 170 | 55,263 | Ref. | 0.2131 | Ref. | 0.0029 | Ref. | 0.0045 |
| Q2 | 171 | 43,592 | 1.030 | (0.938–1.131) | 1.040 | (0.981–1.103) | 1.021 | (0.971–1.073) |
| Q3 | 171 | 36,965 | 0.920 | (0.832–1.017) | 0.928 | (0.871–0.988) | 0.957 | (0.907–1.009) |
| Q4 | 171 | 47,384 | 0.938 | (0.854–1.032) | 0.927 | (0.873–0.983) | 0.939 | (0.893–0.988) |

**Factor 5: Cardiac rehabilitation**

| **Quartile** | **Hospitals (n)** | **Patients (n)** | **OR (95% CI)** | **P for trend** | **OR (95% CI)** | **P for trend** | **OR (95% CI)** | **P for trend** |
|-------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Q1 | 170 | 48,267 | Ref. | 0.0002 | Ref. | 0.0069 | Ref. | 0.0270 |
| Q2 | 171 | 27,808 | 0.986 | (0.874–1.112) | 0.951 | (0.880–1.028) | 0.965 | (0.904–1.031) |
| Q3 | 171 | 46,916 | 0.942 | (0.859–1.033) | 0.952 | (0.889–1.009) | 0.988 | (0.940–1.038) |
| Q4 | 171 | 60,213 | 0.839 | (0.786–0.919) | 0.929 | (0.878–0.983) | 0.952 | (0.908–0.999) |
into 5 factors comprising “Interventional cardiology”, “Cardiovascular surgery”, “Pediatric cardiology”, “Electrophysiology” and “Cardiac rehabilitation”. Factor analysis is a method of finding new factors by detecting the strength of the relationship of factor loadings from multiple collinear items. Using this approach, we can aggregate a number of factors that are highly multicollinear and have strong entanglement with each other, which is called “reducing the dimensions”. The factor name was determined by referring to the factor loadings obtained from factor analysis. As a quality indicator for HF has not yet been established, this method selected objectively rather than arbitrarily. In the sensitivity analysis, the representative item of each factor was selected by referring to the factor loading quantity, and a similar tendency as this study was shown.

The model extracted by exploratory factor analysis was clinically feasible and could represent a reasonably strong model. This study was not able to explain the composition of the factor clusters and underlying conditions; however, our findings confirmed several relationship patterns in HF care.

Prognostic Information

Hospital practice factors such as “Pedicardiology,” “Electrophysiology,” and “Cardiac rehabilitation” were associated with lower mortality in hospitalized HF patients. The “Pedicardiology” factor was associated with better prognosis for HF. However, we should interpret the results carefully because the number of hospitals that had pedicardiology departments was 22% of the total and 99% of interventions belonged to quartile 4. Therefore, we consider the direct prognostic influence of this factor may be limited. The higher “Pedicardiology” activity may have been related to the number of hospital beds (quartile 1: 292±102 vs. quartile 4: 639±259) and the number of cardiologists (quartile 1: 4.2±1.9 vs. quartile 4: 15.2±13.0), because pedicardiologists are highly specialized.

It showed the higher factor score of “Electrophysiology” was associated with better early outcomes in HF. A large number of HF patients are complicated with atrial fibrillation (AF).2021 and HF patients with AF have a poor prognosis.2223 Many reports have shown that a single non-medications treatment improved prognosis in the chronic phase of HF, such as ICD,24 cardiac resynchronization therapy (CRT),25,26 or catheter ablation.27,28 AF and ventricular tachycardia are common arrhythmias in HF patients, so their management is essential for better outcomes. Higher device implantation activity, such as implantation of pacemaker, ICD and CRT, and catheter ablation, is reasonable to improve the management of HF and reduce cardiovascular deaths. In this study, we created a new complex variable called “Electrophysiology” for existing variables in the JROAD-DPC database using exploratory factor analysis; the high hospital activity of the total “Electrophysiology” factor improved early outcomes in HF. It is important to recognize that the results were not only influenced by the treatment itself and our analysis did not conclude that the patients who underwent device implantation and catheter ablation had better outcomes.

Higher “Cardiac rehabilitation” scores were associated with lower early mortality in HF. “Cardiac rehabilitation” has been shown to improve the prognosis in HF by ExTraMATCH (Exercise Training MetaAnalysis of Trials in patients with Chronic Heart failure)²⁹ and HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of exercise training).³⁰ Long-term cardiac rehabilitation improves exercise tolerance and quality of life by reducing inflammatory cytokines, angiotensin II, and B-type natriuretic peptide, and by normalizing autonomic derangement and neurohumoral activation, thereby reducing the rate of hospitalization for HF and improving the prognosis in HF.³¹ Moreover, rehabilitation during the early phase of hospitalization improves the rates of disuse syndrome, which decreases cardiac function, by improving general condition and muscular strength.³² No randomized clinical trial has shown that cardiac rehabilitation improves in-hospital mortality in HF; however, the present findings suggest that cardiac rehabilitation activity is related to better early outcomes in HF patients.

In contrast, hospital practice factors such as “Interventional cardiology” were associated with higher mortality in hospitalized HF patients. One study reported that the introduction of a CCU reduced mortality rates even though the number of hospitalized cases and their severity increased.³³ The severity of hospitalized HF patients might rise with the higher score of “Interventional cardiology”, because as the quartile of factor 1 went up, the rate of presence of a CCU also tended to increase (Q1 60%, Q2 83%, Q3 95%, Q4 98%). Other items associated with emergency hospitalization, such as emergency PCI, has the larger factor loading score in factor 1. Therefore, factor 1 may be related with higher mortality. On the other hand, there is another fact that some of the hospitals performing many coronary interventions are not always equipped with cardiac rehabilitation and electrophysiological procedures, which may result in the outcome of HF patients regardless of the involvement of ischemic heart disease. For example, 35% of high-volume centers for cardiac intervention (Q4 of factor 1) are not equipped for cardiac rehabilitation.

The “Cardiovascular surgery” factor was not associated with short-term outcomes in HF, possible because there were not many patients who needed cardiac surgery such as urgent CABG and valve replacement in the acute phase of hospitalization. Most highly invasive cardiac surgeries are performed during the stable phase of HF.

Study Limitations

The findings of the present study should be interpreted in light of certain limitations. First, the purpose of this study was not to promote a single set of hospital factors as a superior “package” for individual patient prognosis, but to extend our understanding of the interdependence of hospital practices by the prognostic information of the clustered hospital factors. Therefore, the clinical implications of these findings should be considered with caution. Second, we hypothesized that patient outcomes are determined by hospital factors. However, hospital performance factors other than hospital case volume that could improve the inhospital mortality in HF have not been examined. Statistical models combining hospital practice factors and conventional patient factors in the JROAD-DPC database might provide superior prognostic information. Third, medical information, including hemodynamics, clinical conditions, the severity of HF at admission and long-term prognosis, was not investigated in this study. Therefore, the information on patients’ factors was limited and it was also difficult to evaluate the achievement of guideline-based therapies for HF. Medication using ß-blockers and RAS inhibitors prescription at discharge in this dataset was relatively low as reported.8 The average age of patients in
this study was 77.8 years, which was similar to other large registries in Japan in the past; in ATTEND (n=4,842, 2007–2011) it was 73 years, in WET-HF (n=2,531, 2011–2015) it was 75 years, and in REALITY-AHF (n=1,682, 2014–2015) it was 78 years. Because the ratios of patients with ejection fraction (EF) >40 were 47%, 59%, and 63%, respectively, we assumed the percentage of patients with HF with preserved EF (HFpEF) was probably also high in the patients of this study. Therefore, we speculate a high percentage of HFpEF patients may explain the low prescription rate of RAS inhibitors and β-blockers. Fourth, although we used the same criteria as in a previous report for creating the dataset, the reliability and certainty of HF diagnosis from International Classification of Diseases-10 codes need to be clarified in the future. Finally, exploratory factor analyses were applied to only a limited number of facilities included in the JROAD-DPC. We cannot apply our findings to other non-certified hospitals. Larger prospective trials are required to further explore the utility of exploratory factor analysis for this application.

Conclusions
Clustering of multiple hospital factors using exploratory factor analysis was feasible and could be useful for exploring the interactions among different hospital practices in HF care. Hospital practice factors, including various cardiovascular care factors, were associated with mortality of HF patients. Hospital practice factors related to pediatric cardiology, electrophysiology, and cardiac rehabilitation may be associated with lower mortality rates in hospitalized HF patients.

Sources of Funding
The present work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (T.I.: 17K09582, H.T.: 15H04815), Health Sciences Research Grants from the Japanese Ministry of Health, Labour and Welfare, and AMED grant (19ek0109339h0002 (H.T.), 19ek0210080h0003 (H.T.) 19 ek0210097h0003 (H.T.). The funders had no role in the manuscript for publication.

IRB Information
The protocol was approved by Kyushu University Institutional Review Board for Clinical Research (No. 28-381).

Disclosures
H.T. received remuneration for presentations from Bayer, Pfizer, Ohtsuka Pharm, Daiichi-Sankyo, Tanabe-Mitsubishi, Boehringer-Ingelheim, Novartis, and Bristol-Myers Squibb, manuscript fees from Nihonrinshosha, research funding from Daiichi-Sankyo, Tanabe-Mitsubishi, Boehringer-Ingelheim Japan, JT Pharm, and IQVIA, scholarship funds from Daiichi-Sankyo, Tanabe-Mitsubishi, and Tejin-Pharm.
T.A. received research grant from the Japan Agency for Medical Research and Development, a research grant from Daiichi-Sankyo, scholarship funds from Biotronik Japan, Medtronic Japan, Win International, Medical System Network, and Hokuyaku Takeyama Holdings, Inc., and honoraria from Daiichi-Sankyo, Ono Pharmaceutical, Boehringer-Ingelheim Japan, Bayer's Pharmaceuticals, and Bristol-Myers Squibb.

References
1. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: A consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 2015; 17: 544 – 558.
2. Cohen-Solal A, Laribi S, Ishihara S, Vergaro G, Baudet M, Logeart D, et al. Prognostic markers of acute decompensated heart failure: The emerging roles of cardiac biomarkers and prognostic scores. Arch Cardiovasc Dis 2015; 108: 64 – 74.
3. Adams KF Jr, Fonarow GC, Emerman CL, Lelemtel TH, Costanzo MR, Ahnemann ET, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209 – 216.
4. Nissen MS, Brutsaert D, Dickstein K, Dreuxler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. Eur J Heart Fail 2006; 8: 2725 – 2736.
5. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A, ICARE-CARD Heart Failure Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 2006; 70: 1617 – 1623.
6. Sato N, Kajimoto K, Keida T, Mizuno M, Minami Y, Yamino D, et al. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 2013; 77: 944 – 951.
7. Ross JS, Normand SL, Wang Y, Ko DT, Chen J, Drye EE, et al. Hospital volume and 30-day mortality for three common medical conditions. N Engl J Med 2010; 362: 1110 – 1118.
8. Yamada S, Nakao K, Nishimura K, Miyawaki Y, Sumita Y, Shishido T, et al. The current status of cardiovascular medicine in Japan: Analysis of a large number of health records from a nationwide claim-based database, JROAD-DPC. Circ J 2016; 80: 2327 – 2335.
9. Knoll GJ, Gray M. Factor analysis model evaluation through likelihood cross-validation. Stat Methods Med Res 2007; 16: 77 – 102.
10. Norm OR, Hatcher L. A step-by-step approach to using SAS® for factor analysis and structural equation modeling, 2nd edn. SAS Institute Inc., Cary, NC, 2013.
11. Tziakas DN, Chalikias GK, Kasic J, Kekes A, Hatzinkokolou EL, Stakos DA, et al. Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: A factor analysis approach. Atherosclerosis 2007; 193: 196 – 203.
12. Manhenke C, Orr S, von Haselth S, Woller KC, Ueland T, Aukrust P, et al. Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. Int J Cardiol 2013; 166: 729 – 735.
13. Egnor NS, Barinas-Mitchell E, Criqui MH, Allison MA, Ix JH, Jennings NS, et al. An exploratory factor analysis of inflammatory and coagulation markers associated with femoral artery atherosclerosis in the San Diego Population Study. Thromb Res 2018; 164: 9 – 14.
14. Allen LA, Fonarow GC, Grau-Sepulveda MV, Hernandez AF, Peterson PN, Partovian C, et al. Hospital variation in intravenous inotropic use for patients hospitalized with heart failure: Insights from Get With The Guidelines, Circ Heart Fail 2014; 7: 251 – 260.
15. Kulkarni VT, Kim N, Dai Y, Dharmarajan K, Safavi KC, Bikdeli B, et al. Hospital variation in noninvasive positive pressure ventilation for acute decompensated heart failure. Circ Heart Fail 2014; 7: 427 – 433.
16. Khera R, Pandey A, Kumar N, Singh R, Bano S, Golwala H, et al. Variation in hospital use and outcomes associated with pulmonary artery catheterization in heart failure in the United States. Circ Heart Fail 2016; 9: pii: e003226.
17. Al-Damluji MS, Dzara K, Hodshon B, Punnanithinont N, Krumbholz HM, Chaudhry SL, et al. Hospital variation in quality of discharge summaries for patients hospitalized with heart failure exacerbation. Circ Cardiovasc Qual Outcomes 2015; 8: 77 – 86.
18. Akpa OM, Afobali RF, Fowobaje KR. Psychometric properties and confirmatory structure of the strengths and difficulties questionnaire in a sample of adolescents in Nigeria. Int J Psychiat Med 2016; 44: 98 – 106.
19. Williams AJ, Wyatt KM, Williams CA, Logan S, Henley WE. Exploring the potential of a school impact on pupil weight status: Exploratory factor analysis and repeat cross-sectional study of the National Child Measurement Programme. PLoS One 2015; 10: e0145128.
20. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D’Agostino RB Sr, et al. Development of a risk score for atrial fibrillation. Circulation. Eur J Heart Fail Study: A community-based cohort study. Lancet 2009; 373: 739 – 745.
21. Hamaguchi S, Yokoshiki H, Kinugawa S, Tsuchihashi-Makaya M, Yokota T, Takeshita A, et al. Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 2084–2090.

22. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyes L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 2009; 11: 676–683.

23. Mountantonakis SE, Grau-Sepulveda MV, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: An analysis of get with the guidelines-heart failure. Circ Heart Fail 2012; 5: 191–201.

24. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225–237.

25. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140–2150.

26. Cleland JG, Daubert J, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539–1549.

27. Bunch TJ, May HT, Bair TL, Jacobs V, Crandall BG, Cutler M, et al. Five-year outcomes of catheter ablation in patients with atrial fibrillation and left ventricular systolic dysfunction. J Cardiovasc Electrophysiol 2015; 26: 363–370.

28. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordans L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018; 378: 417–427.

29. Piepoli MF, Davos C, Francis DP, Coats AJ; ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004; 328: 189.

30. Keteyian SJ, Leifer ES, Houston-Miller N, Kraus WE, Brawner CA, O’Connor CM, et al. Relation between volume of exercise and clinical outcomes in patients with heart failure. J Am Coll Cardiol 2012; 60: 1899–1905.

31. Gien S, Adams V, Möbius-Winkler S, Linke A, Erbs S, Yu J, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 861–868.

32. Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: A randomised controlled trial. Lancet 2009; 373: 1874–1882.

33. Katz IN, Shah BR, Volz EM, Horton JR, Shaw LK, Newby LK, et al. Evolution of the coronary care unit: Clinical characteristics and temporal trends in healthcare delivery and outcomes. Crit Care Med 2010; 38: 375–381.

34. Shiraishi Y, Kohsaka S, Sato N, Takano T, Kitai T, Yoshikawa T, et al. 9-year trend in the management of acute heart failure in Japan: A report from the National Consortium of acute heart failure registries. J Am Heart Assoc 2018; 7: e008687.

Supplementary Files
Please find supplementary file(s);
http://dx.doi.org/10.1253/circj.CJ-19-0759